ClinicalTrials.gg

Program

sebetralstat

Also written as “KVD900 600 mg”, “KVD900 300 mg” and “KVD900”.

Its studies are mostly in Angioedemas, Hereditary, led by Chiesi Farmaceutici.

Furthest: phase 4, since Jun 12, 20267 company-led studies, 1 open or runningNext primary completion: Nov 29, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceutici71 open or runningphase 4since Jun 12, 2026Dec 20, 2019Nov 29, 2027phase 4 · NCT07654829

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2019First study: phase 2 study in Angioedemas, HereditaryFirst studyNCT04208412 · 84 enrolled · United States, Austria, Czechia and more
  2. Mar 9, 2020Phase 1 study in Angioedemas, HereditaryNCT04349800 · 84 enrolled · United Kingdom
  3. Feb 4, 2022Phase 3 study in Angioedemas, HereditaryNCT05259917 · 136 enrolled · United States, Australia, Bulgaria and more
  4. Aug 11, 20222 phase 3 studies in Angioedemas, HereditaryNCT05511922, NCT05505916
  5. Jun 14, 2024Phase 3 study in Angioedemas, HereditaryNCT06467084 · 36 enrolled · United States, Canada, France and more
  6. Jun 12, 2026Phase 4 study in Angioedemas, HereditaryNCT07654829 · 100 planned · United States

Ahead

  1. Nov 29, 2027Primary completion: phase 4 study in Angioedemas, HereditaryNCT07654829

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07654829Angioedemas, Hereditary · United States4RecruitingNov 29, 2027100
NCT06467084Angioedemas, Hereditary · United States, Canada, France and more3CompletedJan 15, 202636
NCT05511922Angioedemas, Hereditary · United States, Australia, Austria and more3CompletedMay 27, 202611
NCT05505916Angioedemas, Hereditary · United States, Australia, Austria and more3CompletedMay 27, 2026145
NCT05259917Angioedemas, Hereditary · United States, Australia, Bulgaria and more3CompletedDec 31, 2023136
NCT04349800Angioedemas, Hereditary · United Kingdom1CompletedSep 10, 201884
NCT04208412Angioedemas, Hereditary · United States, Austria, Czechia and more2CompletedDec 8, 202084

How it is read

Names in the registry

  • “KVD900 600 mg”, 5 entries
  • “KVD900 300 mg”, 3 entries
  • “KVD900”, 2 entries
  • “KVD900 150 mg”, 1 entry
  • “Drug: KVD900 300 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.